REGN — Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Increased 17% year-over-year to $4.3 billion.
• Non-GAAP Earnings Per Share: Grew 11% to $14.29, with net income of $1.5 billion.
• Sanofi Collaboration Revenue: Reached an all-time high of $2.2 billion, with Regeneron’s share of profits up 59% year-over-year.
• EYLEA HD Sales: Nearly $600 million, up 52% year-over-year; EYLEA sales in the U.S. were $412 million, down 45% year-over-year due to conversion to EYLEA HD.
• Libtayo Sales: Global net product sales reached $489 million, a 29% increase year-over-year.
• Cash Position: Ended the quarter with $15.1 billion in cash and marketable securities.

2. Strategic Updates and Business Highlights

• Dupixent: Global net sales were $6 billion, up 38% year-over-year. Continued growth expected through expansion into new indications and age groups.
• EYLEA HD: Achieved significant growth, with a strong physician demand and expected continued adoption following FDA label expansions.
• Pipeline Progress: Approximately 50 active clinical programs, with key upcoming milestones including FDA decisions on cemdisiran for generalized myasthenia gravis expected in November 2026.
• Collaboration with Sanofi: Productive discussions ongoing to explore further collaboration opportunities, particularly for Dupixent follow-on programs.

3. Forward Guidance and Outlook

• EYLEA HD: Anticipated sequential demand growth in the low to mid-teens for the second half of 2026.
• Dupixent: Expected strong year-over-year growth to moderate in the latter half of 2026 due to tougher prior year comparisons.
• Financial Guidance: Minor refinements to 2026 financial guidance were made, with expectations for increased Sanofi collaboration revenue following the repayment of the development balance.

4. Bad News, Challenges, or Points of Concern

• EYLEA Sales Decline: Traditional EYLEA sales are declining significantly as the market shifts to EYLEA HD, which could impact overall revenue from the retinal franchise.
• Competition: The introduction of aflibercept biosimilars is expected to further pressure EYLEA sales.
• Regulatory Risks: Delays in FDA approvals, particularly concerning the EYLEA HD prefilled syringe, could hinder growth.
• Market Saturation: The competitive landscape in immunology and oncology remains challenging, with multiple treatment options available for conditions like generalized myasthenia gravis.

5. Notable Q&A Insights

• Cash Management: CEO Leonard Schleifer clarified that while Regeneron is cautious about M&A, they are open to opportunities that align with their strategic goals.
• Cemdisiran Launch: The company is preparing for the launch of cemdisiran, emphasizing its differentiated profile in the myasthenia gravis market.
• Sanofi Collaboration: There is optimism regarding the potential to enhance the collaboration with Sanofi, focusing on leveraging shared capabilities and experiences.
• Pipeline Diversification: Regeneron remains committed to a broad pipeline approach, aiming to address various diseases and conditions, including significant investments in ophthalmology and obesity treatments.

Overall, Regeneron reported strong financial results driven by key products, particularly Dupixent and EYLEA HD, while also navigating challenges related to competition and regulatory approvals. The company is focused on maintaining growth through strategic collaborations and a diversified pipeline.